Two Aryl Rings Or Aryl Ring Systems Bonded Directly To The Same Acyclic Carbon Patents (Class 514/648)
-
Publication number: 20100015219Abstract: A solid pharmaceutical composition in the form of a gel capsule containing at least one active ingredient and also at least one gelling agent chosen from cellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylmethylcellulose, sodium carboxymethylcellulose (CMC) and calcium carboxymethylcellulose, and at least one disintegrating agent, the gelling agent and the disintegrating agent being present in a ratio by weight of 0.3 to 0.7/1 and the content by weight of gelling agent(s) being from 10% to 20% of the composition, and method for preparing same.Type: ApplicationFiled: July 25, 2007Publication date: January 21, 2010Applicants: BOUCHARA-RECORDATI, ASSISTANCE PUBLIQUE HOPITAUX DE PARISInventors: Marie-Pierre Berleur, Jean-Claude Chaumeil, Francois Guyon, Jean-Jacques Houri, Thierry Kin, Gilles Le Pallec, Elisabeth Moreau
-
Publication number: 20100008908Abstract: The treatment of heart failure by administering a therapeutically effective amount of an agent that inhibits hypoxia-inducible factor (HIF). Such agents include small molecule chemical agents and biological agents.Type: ApplicationFiled: April 2, 2009Publication date: January 14, 2010Applicant: Isis Innovation LimitedInventors: Houman Ashrafian, Hugh Watkins
-
Publication number: 20100010096Abstract: Methadone is a frequently employed agent for the treatment of drug addiction and the treatment of pain. Methadone prolongs the cardiac action potential, which on the surface electrocardiogram is represented by QT prolongation. This QT prolongation is known to increase the risk for the development of cardiac arrhythmias, especially the form of ventricular tachycardia known as Torsade de Pointes. For this reason, the FDA has inserted a “black box” warning for potential life threatening arrhythmias. The invention described in this application is the surprising finding that the R-isomer of methadone causes less inhibition of the potassium channel, IKr and thus would have less of a chance of causing life threatening arrhythmias. What is claimed is a method of chirally separating methadone with one isomer having less QT prolongation and more analgesic action that would make a superior pharmacologic agent than the racemate R,S methadone.Type: ApplicationFiled: May 18, 2009Publication date: January 14, 2010Inventors: John Charin Somberg, Vasant V. Ranade
-
Publication number: 20090325930Abstract: The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; ??(I-1) formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R? represents 1 to 4 independent hydrogen atoms and the like; and R? represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.Type: ApplicationFiled: August 20, 2009Publication date: December 31, 2009Inventors: Shinichi Hamaoka, Noritaka Kitazawa, Kazumasa Nara, Atsushi Sasaki, Atsushi Kamada, Tadashi Okabe
-
Publication number: 20090311317Abstract: Modified or extended release formulations containing tolterodine and associated methods are disclosed and described. Methods for making and administering said modified release formulations are also disclosed.Type: ApplicationFiled: May 14, 2009Publication date: December 17, 2009Applicant: Capricorn Pharma Inc.Inventors: Subraman Rao CHERUKURI, Venkat N. RAVELLA
-
Publication number: 20090291134Abstract: The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen.Type: ApplicationFiled: May 21, 2009Publication date: November 26, 2009Applicant: JINA PHARMACEUTICALS, INC.Inventors: Ateeq Ahmad, Shoukath M. Ali, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad
-
Publication number: 20090281194Abstract: The present invention relates to novel combinations suitable for the treatment or amelioration of pain of various genesis or aetiology, which comprise, as active ingredients, at least one cannabinoid receptor binding compound, in particular a cannabinoid receptor binding naphthalene derivative, and at least one opioid, to their preparation, to their use as medicaments and to medicaments comprising them.Type: ApplicationFiled: March 2, 2009Publication date: November 12, 2009Inventors: Donald Johns, Thomas George Evans
-
Publication number: 20090234019Abstract: The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wherein R1 is C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; Z is NH, NCH3, O, S, or CH2; Y is NH, O, or CH2 with the proviso that Y and Z are not the same; R2 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy; m and n are independently selected from integers ranging from 1-5 with the proviso that m+n=an integer ranging from 2-9; and R3 is H, halo, NH2, C1-C4 alkyl, hydroxy, or C1-C4 alkoxy.Type: ApplicationFiled: August 22, 2005Publication date: September 17, 2009Inventors: Lloyd S. Gray, Timothy L. MacDonald, Doris M. Haverstick, Jaclyn R. Patterson, William F. McClamont
-
Patent number: 7589056Abstract: Use of a polylysine, polyamidoamine or polypropylenimine dendrimer having naphthyl disulphonate terminal groups as a topically applied agent in prophylaxis or treatment of sexually transmitted diseases.Type: GrantFiled: March 28, 2002Date of Patent: September 15, 2009Assignee: Starpharma Pty. Ltd.Inventors: Barry Ross Matthews, George Holan, Peter Karellas, Scott Andrew Henderson, David Francis O'Keefe
-
Patent number: 7589127Abstract: The present invention relates to Mannich base antimalarial aminoalkylphenol compounds and their use against protozoa of the genus Plasmodium, particularly emerging strains of drug-resistant Plasmodia. This invention further relates to compositions containing such compounds and a process for making the compounds. This and other aspects of the invention are realized upon review of the entire specification.Type: GrantFiled: June 20, 2003Date of Patent: September 15, 2009Assignee: Merck & Co., Inc.Inventors: Conrad P. Dorn, Mary Ann Powles, Thomas F. Walsh, Matthew J. Wyvratt
-
Publication number: 20090221527Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.Type: ApplicationFiled: January 31, 2006Publication date: September 3, 2009Applicants: CEPTION THERAPEUTICS, INC., TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Mark I. Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiao
-
Patent number: 7582653Abstract: Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.Type: GrantFiled: June 15, 2007Date of Patent: September 1, 2009Assignee: Council of Scientific & Industrial ResearchInventors: Sangita, Atul Kumar, Man Mohan Singh, Girish Kumar Jain, Puvvada Sri Ramanchandra Murthy, Suprabhat Ray
-
Publication number: 20090214665Abstract: An oral controlled release pharmaceutical composition for muscarinic receptor antagonist, preferably tolterodine, that employs a drug core, a rapidly disintegrating or rapidly dissolving coating applied to the drug core and a controlled release coating.Type: ApplicationFiled: February 26, 2008Publication date: August 27, 2009Inventors: Felix S. Lai, Richard Ting, Lee Foong Siew, King Yu-Kuang Chuang, Sibel Ucpinar
-
Publication number: 20090203796Abstract: The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer.Type: ApplicationFiled: March 4, 2009Publication date: August 13, 2009Inventor: Elisabeth LE NESTOUR
-
Publication number: 20090192228Abstract: Controlled-release tolterodine compositions, including controlled-release particles, pellets, granules, and spheres, comprising an inert core, a first layer disposed on the inert core, and a second layer disposed on the first layer are described. Methods for preparing such compositions and methods of treating a variety of disorders are also disclosed.Type: ApplicationFiled: January 27, 2009Publication date: July 30, 2009Applicant: ACTAVIS GROUP PTC EHFInventor: Hui Wang
-
Publication number: 20090186944Abstract: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.Type: ApplicationFiled: January 14, 2009Publication date: July 23, 2009Inventors: Philippe ROUANET, Dominique Salin Drouin, Jacques Wepierre
-
Patent number: 7560491Abstract: A series of Z-stilbenes derivatives are disclosed, which have the structure as shown by formula 1. In the structure of formula 1, X is hydrogen, NHR, or nitro group, and R is hydrogen. Y and Z is independently hydrogen, halogen, C1-C10 alkyl, or C1-C10 alkoxyl. Furthermore, A is hydrogen, hydroxyl, or amino group. The compounds of the present invention have both aqueous solubility and anti-tumor activity. The Z-stilbenes derivatives of the present invention can further include a pharmaceutical carrier to form pharmaceutical compositions as potent anti-mitotic agents and anti-cancer agents.Type: GrantFiled: January 19, 2007Date of Patent: July 14, 2009Assignees: Taipei Medical University, National Health Research InstitutesInventors: Jing-Ping Liou, Jang-Yang Chang
-
Publication number: 20090176738Abstract: There is provided a means of applying a heated medicament to the skin and concurrently hydrating the skin thus raising the efficacy of administration.Type: ApplicationFiled: December 9, 2008Publication date: July 9, 2009Inventors: Leonard Mackles, William Bess
-
Patent number: 7538249Abstract: Racemic tolterodine free base in crystalline form, tolterodine with improved purity, compositions and uses thereof, and processes of preparing the same.Type: GrantFiled: December 23, 2004Date of Patent: May 26, 2009Assignee: Cipla LimitedInventors: Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao
-
Publication number: 20090130171Abstract: Implantable medical devices, such as catheters, treated with a high concentration of gentian violet, and methods of preparing these medical devices are provided.Type: ApplicationFiled: October 2, 2008Publication date: May 21, 2009Inventors: Hiep Do, Daniel J. Spangler, Joel Rosenblatt, Barrett Remington, Onajite Okoh
-
Publication number: 20090130232Abstract: The present invention is a composition and method for treating oral lesions. A composition for treatment of oral lesions may comprise: (a) an anesthetic composition; (b) an antifungal composition; (c) a steroid composition; (d) an antihistamine composition; and (e) an antacid composition, wherein the therapeutic composition is substantially free of alcohol. A method for treatment may comprise: (a) administering to a patient an effective amount of a composition, the therapeutic composition comprising: (i) an anesthetic composition; (ii) an antifungal composition; (iii) a steroid composition; (iv) an antihistamine composition; and (v) an antacid composition, wherein the therapeutic composition is substantially free of alcohol. A method of producing a composition may comprise: combining (a) an anesthetic composition, (b) an antifungal composition, (c) a steroid composition, (d) an antihistamine composition, and (e) an antacid composition, wherein the therapeutic composition is substantially free of alcohol.Type: ApplicationFiled: November 20, 2007Publication date: May 21, 2009Inventor: Mohammed Zahra
-
Patent number: 7531578Abstract: Disclosed are novel compositions and novel methods for the creation of both the novel compounds and known compounds. Also disclosed are methods for use of the novel compounds for treating a variety of diseases relating to decreasing or preventing activation of estrogen receptors and/or estrogen related receptors.Type: GrantFiled: September 16, 2004Date of Patent: May 12, 2009Assignee: City of HopeInventors: Barry Forman, Donna Yu
-
Publication number: 20090117207Abstract: A method of treating a poison-caused pathology in an individual subject is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier, to an individual subject exposed to a poison. Optionally, an inventive method further includes administering a therapeutic agent to inhibit poison-caused pathology. A composition according to the invention is described which includes a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier.Type: ApplicationFiled: November 29, 2005Publication date: May 7, 2009Inventors: Csaba K. Zoltani, Gennady E. Platoff, Steven I. Baskin
-
Patent number: 7524866Abstract: This invention provides: 1) a method of treating androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 2) a method of preventing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of Bone Mineral Density (BMD) in a male subject suffering from prostate cancer; 3) a method of suppressing or inhibiting androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer; and 4) a method of reducing the risk of developing androgen-deprivation induced osteoporosis and/or bone fractures and/or loss of BMD in a male subject suffering from prostate cancer, by administering to the subject a pharmaceutical composition comprising an anti-estrogen agent and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof.Type: GrantFiled: February 17, 2004Date of Patent: April 28, 2009Assignee: GTx, Inc.Inventors: Mitchell S. Steiner, Sharan Raghow, Karen A. Veverka
-
Publication number: 20090105348Abstract: A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase and/or aura phase of the migraine headache.Type: ApplicationFiled: October 17, 2008Publication date: April 23, 2009Inventor: HARRY FISCH
-
Publication number: 20090104206Abstract: Novel etiology and pathogenesis of premenstrual headache and premenstrual migraine are presented and novel treatment methods are provided. Present invention identifies how declining estrogen results in a transient elevation in extracellular calcium concentrations via osteoclast upregulation. The elevated extracellular calcium pathogenesis is then traced, from bone to brain, and includes depolarization of nerves, hyperactive neurotransmitter release, and hyperactive muscle contractility. Treatment methods are provided that target the earliest steps of the underlying etiology, in order to provide the most efficacious treatment possible. The treatment methods presented include use of compounds such as calcitonin and SERMs such as raloxifene.Type: ApplicationFiled: October 19, 2007Publication date: April 23, 2009Inventors: Mark Zamoyski, Justin John Zamoyski
-
Publication number: 20090104119Abstract: The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer based multifunctional compositions and systems for use in disease diagnosis and therapy (e.g., cancer diagnosis and therapy). The compositions and systems comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and monitoring the response to therapy of a cell or tissue (e.g., a tumor).Type: ApplicationFiled: August 25, 2005Publication date: April 23, 2009Inventors: Istvan J. Majoros, Thommey P. Thomas, James R. Baker, Zhengyi Cao, Jolanta F. Kukowska-Latallo
-
Patent number: 7511070Abstract: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.Type: GrantFiled: November 9, 2005Date of Patent: March 31, 2009Assignee: Poniard Pharmaceuticals, Inc.Inventors: David J. Grainger, James C. Metcalfe, Sudhakar Kasina
-
Publication number: 20090082467Abstract: A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase of the migraine headache.Type: ApplicationFiled: September 19, 2008Publication date: March 26, 2009Inventor: Harry FISCH
-
Publication number: 20090069343Abstract: Patients suffering from pruritus or itch may be effectively treated by administering a centrally acting histamine H1 receptor antagonist (e.g., diphenhydramine, triprolidine, hydroxyzine, pyrilamine, promethazine, or chlorpheniramine) and a histamine H4 receptor antagonist (e.g., 5-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone).Type: ApplicationFiled: April 9, 2007Publication date: March 12, 2009Inventors: Paul J. Dunford, Lars Karlsson, Robin L. Thurmond
-
Publication number: 20090062398Abstract: The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 21, 2008Publication date: March 5, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090053285Abstract: A medicament carrier composition includes a medicament and a polymer component including a polyvinylpyrrolidone having a weight average molecular weight of at least 700,000 g/mol. The medicament carrier composition has a viscosity of from 500 to 5,000 cps at 250 C, is substantially free of cellulose, and includes an auxiliary polymer. The medicament carrier composition is used to form a film that is also substantially free of cellulose. The film has a consistent thickness and size, and an increased flexibility and increased moisture resistance due to the polyvinylpyrrolidone. The medicament carrier composition is also used in a method of forming the film. The method includes the steps of providing the medicament and the polymer component. The method also includes the step of combining the polymer component and the medicament to form the medicament carrier composition. The method further includes the step of drying the medicament carrier composition to form the film.Type: ApplicationFiled: April 24, 2006Publication date: February 26, 2009Inventors: Shaukat Ali, Anisul Quadir
-
Publication number: 20090047347Abstract: The present invention provides compositions and methods and for speeding the onset of drug action and reducing the first-pass effect drug metabolism in fast-dispersing drug formulations.Type: ApplicationFiled: August 20, 2008Publication date: February 19, 2009Applicant: AEGIS THERAPEUTICS, INC.Inventor: Edward T. Maggio
-
Publication number: 20090048270Abstract: Methods, compositions and devices for inhibiting neoproliferative changes in blood vessel walls or other anatomical structures. One or more compounds of Formula I or I-A set forth herein are administered systemically and/or locally to human or veterinary patients to deter or prevent unwanted proliferative changes in blood vessels or other anatomical structures. The invention may be used to deter or prevent stenosis or restenosis of arteries following angioplasty and/or stent placement. In one embodiment, there is provided an implantable stent or stent graft from which one or more compounds of the present invention will elute or otherwise be delivered into an affected blood vessel wall.Type: ApplicationFiled: October 30, 2003Publication date: February 19, 2009Inventors: Ralf Koehler, Heike Wulff, Joachim Hoyer, K. George Chandy
-
Publication number: 20090047234Abstract: The present invention concerns a method of administering at least one active pharmaceutical agent to a patient in need thereof, which method comprises the intranasal administration of a composition comprising a therapeutically effective amount of this agent, phospholipids, one or more C2-C4 alcohols and water, wherein the concentrations of the phospholipids and the one or more alcohols in the composition are in the ranges of 0.2 to 10% and 12 to 30% by weight, respectively, with the water content of said composition being not less than 30% by weight, the phospholipids forming vesicles in said composition. Further are disclosed pharmaceutical compositions and combinations suitable for intranasal delivery.Type: ApplicationFiled: March 28, 2008Publication date: February 19, 2009Inventors: Elka Touitou, Biana Godin, Shaher Duchi
-
Publication number: 20090047343Abstract: The present invention relates to a process for stabilizing phenylephrine including drying an acidic solution of phenylephrine and pharmaceutical compositions including stabilized phenylephrine.Type: ApplicationFiled: August 13, 2007Publication date: February 19, 2009Inventors: Hugh Huang, Jonathan Zeszotarski, Anthony Bean, William Michael Nichols
-
Publication number: 20090036415Abstract: The present invention is directed to specific chromosomal rearrangements that are associated with prostate tumors that respond to compounds acting at estrogen receptors. Patients having the TMPRSS2-ERG fusion, may be treated with agonists of the estrogen beta receptor or antagonists of the estrogen alpha receptor.Type: ApplicationFiled: July 23, 2008Publication date: February 5, 2009Applicant: The Brigham and Women's Hospital, Inc.Inventors: Mark Rubin, Kirsten Mertz
-
Publication number: 20090029984Abstract: The invention relates to a pharmaceutical dosage form comprising an analgesic combination for simultaneous or sequential use which comprises a peripherally restricted cannabinoid CB1 receptor agonist having a brain Cmax to plasma Cmax ratio of less than 0.1 and an opioid receptor agonist, as well as to a method for treating pain using said pharmaceutical dosage form.Type: ApplicationFiled: July 6, 2006Publication date: January 29, 2009Applicant: N.V. OrganonInventors: Julia Adam-Worrall, David Robert Hill, Jean Cottney
-
Publication number: 20090022797Abstract: A pharmaceutical composition contains tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used to make various types of immediate release and controlled release dosage forms.Type: ApplicationFiled: July 20, 2007Publication date: January 22, 2009Applicant: MYLAN PHARMACEUTICALS INCInventors: David T. Rossi, Boyong Li, James Paul McCall
-
Publication number: 20090018205Abstract: Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the treatment of migraines include pharmaceutical compositions of trimethobenzamide and diphenhydramine.Type: ApplicationFiled: September 16, 2008Publication date: January 15, 2009Inventor: Foad SALEHANI
-
Publication number: 20090018207Abstract: Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.Type: ApplicationFiled: September 19, 2008Publication date: January 15, 2009Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20090017111Abstract: A controlled release tolterodine bead is formed having a microcrystalline cellulose core, a PVP-containing water soluble coating, a tolterodine drug layer, and a controlled release layer.Type: ApplicationFiled: July 3, 2008Publication date: January 15, 2009Inventor: Dennie J. M. van den Heuvel
-
Publication number: 20090012052Abstract: A method for selecting a female breast cancer patient for AT1 receptor antagonist therapy comprises (a) determining whether the cancer comprises a tumor that is ER+ and/or PR+; and (b) selecting the patient for AT1 receptor antagonist therapy only if the cancer is determined to comprise an ER+ and/or PR+ tumor. A method for treating breast cancer in a female patient further comprises (c) administering to the patient, if so selected, an AT1 receptor antagonist according to a regimen effective to reduce growth, invasiveness and/or metastasis of the tumor.Type: ApplicationFiled: April 9, 2008Publication date: January 8, 2009Applicant: Ore Pharmaceuticals Inc.Inventors: Robert Mark Coopersmith, David William White, Shengfang Jin, Denzyl Fernandes, Xuena Lin
-
Publication number: 20080318982Abstract: This invention relates to the combined use of a PDE5 inhibitor and a muscarinic antagonist in the treatment of lower urinary tract symptoms (LUTS), such as urgency, frequency, nocturia and urge incontinence.Type: ApplicationFiled: December 19, 2006Publication date: December 25, 2008Inventors: Carl Erik Johan Mastrell, Michael Allen Suesserman
-
Publication number: 20080312239Abstract: A method of treatment of erectile dysfunction (ED) comprises the step of administering fispemifene to a subject in need thereof in an amount effective to raise the subject's testosterone level. Fispemifene may be used in combination with a PDE-5 inhibitor in individuals who have failed to respond sufficiently to conventional ED treatment. Methods are also disclosed of treating ED by administering clomifene, enclomifene, ospemifene, toremifene and mixtures thereof in combination with a PDE-5 inhibitor.Type: ApplicationFiled: June 13, 2008Publication date: December 18, 2008Applicant: QUATRX PHARMACEUTICALS COMPANYInventors: Robert L. Zerbe, Alexander Bridges, Risto Lammintausta, Rochelle Hanley, Stuart Dombey
-
Publication number: 20080312199Abstract: The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medullablastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure.Type: ApplicationFiled: December 17, 2007Publication date: December 18, 2008Inventor: Gennadi V. Glinsky
-
Publication number: 20080311196Abstract: A therapeutic regimen is disclosed. The regimen includes a first pharmaceutical dosage form comprising a first therapeutically effective amount of a first antihistamine and an anticholinergic agent; and a second pharmaceutical dosage form comprising a therapeutically effective amount of a second antihistamine and an anticholinergic agent. The second antihistamine either has greater H1 receptor activity or greater sedative effect than the first antihistamine, or is a different dose of the same antihistamine. The regimen comprises indicia for distinguishing between the first and second pharmaceutical dosage forms, wherein one dosage form is for daytime administration and the other is for nighttime administration. The regimen is placed in a prepackaged dispenser prefilled with the pharmaceutical dosage forms and comprising the indicia.Type: ApplicationFiled: June 12, 2008Publication date: December 18, 2008Inventor: Donna F. White
-
Publication number: 20080306036Abstract: Triphenylethylene compounds of formula (I) are provided. The compounds are particularly useful for selective estrogen receptor modulation.Type: ApplicationFiled: November 22, 2006Publication date: December 11, 2008Inventor: Subba Reddy Katamreddy
-
Publication number: 20080293823Abstract: Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine.Type: ApplicationFiled: April 9, 2008Publication date: November 27, 2008Inventors: Dean A. Handley, Larry W. Hardy, Merdad Vaziri Parsey
-
Patent number: 7456222Abstract: Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided. In one embodiment, these methods and compositions are used for the treatment of mycobacterial infections, including, but not limited to, tuberculosis.Type: GrantFiled: July 1, 2005Date of Patent: November 25, 2008Assignees: Sequella, Inc., The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Marina Nikolaevna Protopopova, Richard Edward Lee, Richard Allan Slayden, Clifton E. Barry, III, Elena Bogatcheva, Leo Einck